Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology
Hao Sun, Hsin-Yu Lin, Jieqi Tu, Revathi Ananthakrishnan, Eunhee Kim

TL;DR
This paper reviews and compares current model-assisted dose finding designs in oncology that incorporate both toxicity and efficacy to identify the optimal biological dose, especially for emerging therapies where traditional methods may not apply.
Contribution
It provides a comprehensive comparison of existing dose finding designs that consider toxicity and efficacy, highlighting their performance under various scenarios through extensive simulations.
Findings
STEIN, PRINTE, and BOIN12 outperform others in various metrics
Performance varies with dose-response relationship
Simulation and case study validate findings
Abstract
Traditional phase I dose finding cancer clinical trial designs aim to determine the maximum tolerated dose (MTD) of the investigational cytotoxic agent based on a single toxicity outcome, assuming a monotone dose-response relationship. However, this assumption might not always hold for newly emerging therapies such as immuno-oncology therapies and molecularly targeted therapies, making conventional dose finding trial designs based on toxicity no longer appropriate. To tackle this issue, numerous early phase dose finding clinical trial designs have been developed to identify the optimal biological dose (OBD), which takes both toxicity and efficacy outcomes into account. In this article, we review the current model-assisted dose finding designs, BOIN-ET, BOIN12, UBI, TEPI-2, PRINTE, STEIN, and uTPI to identify the OBD and compare their operating characteristics. Extensive simulation…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
